Exosomes secreted by hypoxic cardiosphere-derived cells enhance tube formation and increase pro-angiogenic miRNA

Journal of Cellular Biochemistry

Volumn 119, Issue 5, 2018, Pages 4150-4160

  Namazi, Helia ^a   Mohit, Elham ^a,b   Namazi, Iman ^c   Rajabi, Sarah ^d   Samadian, Azam ^d   Hajizadeh Saffar, Ensiyeh ^d   Aghdami, Nasser ^d   Baharvand, Hossein ^d,e  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^e UNIVERSITY OF SCIENCE AND CULTURE   (Iran)

Author keywords

angiogenesis; cardiosphere derived cells; exosomes; microRNA

Indexed keywords

MICRORNA; MICRORNA 126; MICRORNA 130A; MICRORNA 210; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CARDIAC MUSCLE CELL; CARDIOSPHERE DERIVED CELL; CELL HYPOXIA; CELL REGENERATION; CELL VIABILITY; CONTROLLED STUDY; EXOSOME; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; HUMAN TISSUE; HUVEC CELL LINE; MTS ASSAY; PRIORITY JOURNAL; UPREGULATION; CYTOLOGY; METABOLISM; MULTICELLULAR SPHEROID; UMBILICAL VEIN ENDOTHELIAL CELL;

EXOSOMES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICRORNAS; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; SPHEROIDS, CELLULAR;

EID: 85044471346     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26621     Document Type: Article

References (51)

1. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. Br Med J. 2012; 344:e356.
2. Gallet R, Dawkins J, Valle J, et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017; 38:201–211.
3. Chen L, Wang Y, Pan Y, et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun. 2013; 431:566–571.
4. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014; 103:530–541.
5. de Couto G, Durvasula P, Ibrahim A, Marbán E. Intracoronary delivery of exosomes secreted by cardiosphere-Derived cells confers cardioprotection wWth delayed administration after ischemia-Reperfusion injury in rats. Circulation. 2014; 130:A15845–A15845.
6. Ibrahim AGE, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014; 2:606–619.
7. Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. Circ Res. 2014; 114:333–344.
8. Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials–an ISEV position paper. J Extracell Vesicles. 2015; 4:30087.
9. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9:654–659.
10. Heusch G. Molecular basis of cardioprotection. Circ Res. 2015; 116:674–699.
11. Greijer A, Van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004; 57:1009–1014.
12. Gray WD, French KM, Ghosh-Choudhary S, et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology novelty and significance. Circ Res. 2015; 116:255–263.
13. Tang YL, Zhu W, Cheng M, et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res. 2009; 104:1209–1216.
14. Silva GV, Litovsky S, Assad JA, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. 2005; 111:150–156.
15. Isner J. Angiogenesis: a “breakthrough” technology in cardiovascular medicine. J Invasive Cardiol. 2000; 12:14A–17A.
16. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95:911–921.
17. Vahdat S, Mousavi SA, Omrani G, et al. Cellular and molecular characterization of human cardiac stem cells reveals key features essential for their function and safety. Stem Cells Dev. 2015; 24:1390–1404.
18. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012; 12:421.
19. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013; 288:34343–34351.
20. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22.1–3.22.29 https://doi.org./10.1002/0471143030.cb0322s30.
21. Sáenz-Cuesta M, Arbelaiz A, Oregi A, et al. Methods for extracellular vesicles isolation in a hospital setting. Front Immunol. 2015; 6:44–55.
22. Fonoudi H, Ansari H, Abbasalizadeh S, et al. A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells. Stem Cells Transl Med. 2015; 4:1482–1494.
23. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52:2745–2756.
24. Kreke M, Smith RR, Marbán L, Marbán E. Cardiospheres and cardiosphere-derived cells as therapeutic agents following myocardial infarction. Expert Rev Cardiovasc Ther. 2012; 10:1185–1194.
25. Zhang Z, Yang J, Yan W, Li Y, Shen Z, Asahara T. Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. J Am Heart Assoc. 2016; 5:e002856.
26. Barile L, Moccetti T, Marbán E, Vassalli G. Roles of exosomes in cardioprotection. Eur Heart J. 2016; 38:1372–1379.
27. Chernyshev VS, Rachamadugu R, Tseng YH, et al. Size and shape characterization of hydrated and desiccated exosomes. Anal Bioanal Chem. 2015; 407:3285–3301.
28. Phuyal S, Skotland T, Hessvik NP, et al. The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells. J Biol Chem. 2015; 290:4225–4237.
29. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124:3748–3757.
30. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S, Chayama K. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J. 2005; 69:1547–1555.
31. Buharalioglu CK, Song CY, Yaghini FA, et al. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol. 2011; 301:H1043–H1055.
32. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011; 31:27–33.
33. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285:17442–17452.
34. Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS ONE. 2014; 9:e88685.
35. Madanecki P, Kapoor N, Bebok Z, Ochocka R, Collawn JF, Bartoszewski R. Regulation of angiogenesis by hypoxia: the role of microRNA. Cell Mol Biol Lett. 2012; 18:37–47.
36. Emanueli C, Shearn AI, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vascul Pharmacol. 2015; 71:24–30.
37. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 2008; 111:1217–1226.
38. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9:677–684.
39. Camps C, Buffa FM, Colella S, et al. Hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14:1340–1348.
40. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009; 69:1221–1229.
41. Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009; 35:856–867.
42. Huang X, Le Q-T, Giaccia AJ. MiR-210–micromanager of the hypoxia pathway. Trends Mol Med. 2010; 16:230–237.
43. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem. 2009; 284:33161–33168.
44. Liu F, Lou Y-L, Wu J, et al. Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res. 2012; 35:182–191.
45. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008; 283:15878–15883.
46. Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009; 284:35134–35143.
47. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008; 79:581–588.
48. Ong S-G, Lee WH, Huang M, et al. Cross talk of combined gene and cell therapy in ischemic heart disease. Circulation. 2014; 130:S60–S69.
49. Fish JE, Santoro MM, Morton SU, et al. MiR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008; 15:272–284.
50. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15:261–271.
51. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature. 2010; 464:1196–1200.